Latest Tapentadol Stories
SHELTON, Conn., Aug. 3, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the dosing of the first patient in a Phase II clinical trial of its peripherally-selective, kappa opioid agonist, CR845, for the treatment of acute post-operative pain.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).